Tag:
Aptuit
Latest Headlines
Latest Headlines
Report: Catalent wants $400M loan to back Aptuit unit buyout
Catalent Pharma Solutions aims to raise $400 million in term loan financing to support the company's buyout of Aptuit's clinical trial supplies business, Bloomberg reported, citing an unnamed...
Catalent snaps up Aptuit's trial supplies ops for $410M
Pumping up its clinical trial services muscle, Catalent Pharma announced it is buying Aptuit's clinical trial supply business for $410 million in cash. Aptuit, a contract research and manufacturing
GSK aims for biotech attitude at R&D ops
Biotech thinking is in. The Big Pharma mindset is out. And you only have to stroll through the halls of GlaxoSmithKline's shrinking R&D ops to find telltale signs of the shift in development
Aptuit plans job cuts
Aptuit says it is planning to cut jobs in the U.K., but hasn't said how many workers face the axe, saying only that it is repositioning its resources in light of current economic conditions. The U.S.
ALSO NOTED: GSK to commercialize Lunesta; second headline; and much more...
> GlaxoSmithKline has signed on to commercialize Sepracor's insomnia drug Lunesta, agreeing to pay $20 million up front and up to $155 million in total for milestones and licensing fees. Glaxo
